Featured Posters & Presentations
Lyfgenia
LentiGlobin Gene therapy in patients with sickle cell disease: Updated interim results from HGB-206.
Authors: Thompson AA.
Zynteglo
Efficacy and safety of LentiGlobin gene therapy in patients with transfusion dependent β-thalassemia and non-β0/β0 genotypes: updated results from the completed phase 1/2 Northstar and ongoing phase 3 Northstar-2 studies.
Authors: Porter JB.
Zynteglo
An observational study to evaluate the routine management, healthcare resource use and outcomes for patients with transfusion-dependent β-thalassaemia treated in the United Kingdom: an interim analysis.
Authors: Ryan K.